Repositioning Candidate Details
| Candidate ID: | R1403 |
| Source ID: | DB11772 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Pilaralisib |
| Synonyms: | Pilaralisib |
| Molecular Formula: | C25H25ClN6O4S |
| SMILES: | COC1=CC=C(Cl)C(NC2=C(NS(=O)(=O)C3=CC(NC(=O)C(C)(C)N)=CC=C3)N=C3C=CC=CC3=N2)=C1 |
| Structure: |
|
| DrugBank Description: | Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others. |
| CAS Number: | 934526-89-3 |
| Molecular Weight: | 541.02 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | In preclinical studies, Pilaralisib slowed tumor growth or caused tumor shrinkage in multiple preclinical cancer models, including breast, lung, ovarian, and prostate cancers, and gliomas. Pilaralisib has also been shown to enhance the anti- tumor effects of several chemotherapeutic agents and an inhibitor of epidermal growth factor receptor (EGFR) in preclinical cancer models. |
| DrugBank MoA: | Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. |
| Targets: | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform |
| Inclusion Criteria: | Therapeutic strategy associated |
